This article was originally published in GenomeWeb News on November 2nd 2011
“UK genotoxicity assay firm Gentronix and French personalized medicine company BioQuanta SA recently announced a deal for the commercialization of services based on BioQuanta’s Mitoxis functional metabolomics platform.
Under the agreement, Gentronix will distribute Mitoxis services worldwide, providing researchers access to more than 70 discrete assays covering functional metabolism necessary for the early detection of toxicity liabilities, including …”
Continue reading this article at GenomeWeb by clicking here. In order to access the article, you must have a registered account with the GenomeWeb Intelligence Network. Don’t worry, it’ free.